Retatrutide 15MG is a 15-milligram format of retatrutide, a synthetic peptide investigated as a multi receptor agonist in metabolic research. Studies have examined retatrutide in the context of incretin and glucagon signaling pathways, including receptor activity linked to energy balance. Researchers commonly use it in controlled laboratory settings where peptide receptor pharmacology is evaluated.

Retatrutide 20MG is a 20-milligram format of retatrutide, a synthetic incretin-mimetic peptide designed for multi-receptor research. Studies have examined retatrutide in preclinical and clinical settings involving GLP-1, GIP, and glucagon receptor signaling and downstream metabolic endpoints.

Retatrutide 36MG is a 36-milligram format of retatrutide, a synthetic peptide agonist studied for its activity across multiple metabolic hormone receptor pathways. Researchers investigate retatrutide in preclinical and clinical settings focused on energy balance, glycemic control, and body weight regulation. Its multi-target design makes it a common comparator in studies of incretin and glucagon signaling.

Retatrutide 40MG is a 40-milligram format of retatrutide, a synthetic incretin peptide analogue studied as a multi receptor agonist in metabolic research. Researchers have investigated retatrutide in preclinical and clinical study settings involving incretin signaling pathways and energy balance physiology.

Retatrutide 60MG is a 60-milligram format of retatrutide, a synthetic peptide investigated as a multi receptor agonist in metabolic research. Studies have examined retatrutide in the context of GLP 1, GIP, and glucagon receptor signaling, primarily in preclinical and clinical research settings.